{"disease":{"id":"type-1-interferonopathies","name":"type 1 interferonopathies"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06878365","title":"A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":16,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT07364513","title":"Phase 1b Safety Study of IMSB301 in Type 1 Interferonopathies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":6,"lead_sponsor_name":"ImmuneSensor Therapeutics Inc.","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}